ACHIEVE LIFE SCIENCES, INC. (ACHV) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-16

Key Insights

Achieve Life Sciences, Inc. has entered into a $180 million private placement with institutional and accredited investors to fund a Phase 3 clinical trial for their smoking cessation drug cytisinicline, as well as commercialization efforts.
The private placement includes the issuance of 49.4 million shares of common stock, pre-funded warrants, and common warrants that could provide an additional $173.8 million in proceeds if fully exercised.
The company has also entered into a registration rights agreement to register the resale of the shares issued in the private placement, providing liquidity for investors.

Want the newest filings?

This analysis covers the filing from 2026-04-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-24

Achieve Life Sciences, Inc. reported its financial results for the fourth quarter and full year 2025, providing investors an update on the company's recent performance.
The press release indicates that the company's financial condition and operations remain stable, with no significant changes or surprises reported.
Overall, the filing appears to be a routine update on the company's financial performance, without any major events or developments that would significantly impact investors.

Other reports for ACHIEVE LIFE SCIENCES, INC.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.